REGENATIVE LABS STUDY OPENS DOOR TO ADVANCED TREATMENT FOR DEGENERATING TISSUE IN KNEE JOINTS

PENSACOLA, Florida., August 22, 2022 /PRNewswire/ — Regenative Labs, a leading manufacturer of HCT/P, has co-authored an MDPI study demonstrating the benefits of allograft tissue, such as its Wharton jelly products, in the treatment of knee joint degeneration .

Also known as osteoarthritis (OA), knee degeneration is the most common joint disease in adults worldwide. Currently, there are 33 million adults in United States living with osteoarthritis, and this number is expected to reach 67 million adults with arthritis by 2032.

While osteoarthritis typically affects older people, it is estimated that working-age adults (45-64) will account for one-third of all new cases over the next 10 years. This bimodal population group is the subject of intense research. Beginning with the degeneration of cartilage in the knee joint itself, osteoarthritis inevitably leads to pain, instability, loss of function and disability.

As noted in the Regenative Labs MDPI study, the current standard of care for symptomatic knee osteoarthritis and articular cartilage degeneration is symptom alleviation with steroid-based anti-inflammatories, transient Visco supplementation with hyaluronic acid or inconsistent and indescribable doses of platelet-rich plasma. or bone marrow aspirate concentrate.

Instead of focusing on symptom relief, Regenative Labs sought to create a non-surgical, cutting-edge class of perinatal tissue allografts to supplement collagen extracellular matrices in weight-bearing joints such as the knee.

Some patients with osteoarthritis have observed adverse joint events after traditional treatment, such as intra-articular corticosteroid injection (IACS), including accelerated progression of osteoarthritis, subchondral insufficiency fracture, complications osteonecrosis and rapid joint destruction with bone loss. (1).

This is in direct contrast to Regenative Labs Wharton Jelly Allografts which have proven a 32% decrease in VAS (pain) scores at 90 days after a single application to degenerated tissue. Regenative Labs believes this research opens the door to homologous use of allograft applications for cartilage degeneration in the knee as well as other major and minor load-bearing joints and the spine.

“This is really just the beginning of the potential benefits and uses of allograft tissue,” said Regenative Labs CEO, Tyler Barrette. “We are committed to continuously improving the standard of care for the regenerative medicine community while simultaneously facilitating the most clinically relevant outcomes for patients.”

About Regenerative Labs: Regenative Labs manufactures regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgical centers to continuously monitor and improve patient progress and outcomes for new product development. Trained by seasoned industry professionals familiar with the daily challenges of healthcare innovation, the company provides effective, non-addictive and non-invasive options for patients. Regenative Labs has a dedicated laser research and product development team that follows FDA guidelines for minimal handling for homologous use. The company adheres to AATB and FDA guidelines.

Learn more on the Regenative website: www.regenativelabs.com

  1. Kompel, AJ, Roemer, FW, Murakami, AM, Diaz, LE, Crema, MD and Guermazi, A. (2019). Intra-articular corticosteroid injections in the hip and knee: perhaps not as safe as thought? Radiology, 293(3), 656-663.

SOURCE Regenerative Laboratories

About Antoine L. Cassell

Check Also

Posters emphasize the prevalence and need for prompt treatment of RVO

Posters presented at the annual meeting of the American Academy of Ophthalmology showed that patients …